ASX:SNT Syntara (SNT) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Syntara Stock (ASX:SNT) 30 days 90 days 365 days Advanced Chart Get Syntara alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewSyntara Limited operates as a clinical stage drug development company that focuses on blood-related cancers. Its lead product candidate is PXS-5505, which is in phase 2 trial for the bone marrow cancer myelofibrosis, which causes a build-up of scar tissue leading to loss of red and white blood cells and platelets. The company was formerly known as Pharmaxis Ltd and changed its name to Syntara Limited in December 2023. Syntara Limited was incorporated in 1998 and is headquartered in Frenchs Forest, Australia.Read More… Receive SNT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Syntara and its competitors with MarketBeat's FREE daily newsletter. Email Address SNT Stock News HeadlinesSyntara Limited Raises A$15 Million Through New Share IssuanceFebruary 19, 2025 | tipranks.comSyntara Limited Announces New Security Issuance on ASXFebruary 19, 2025 | tipranks.comGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which is why I'm recommending ONE coin to all investors right now. February 23, 2025 | Crypto 101 Media (Ad)Syntara Limited Announces ASX Quotation of SecuritiesJanuary 21, 2025 | tipranks.comSyntara Limited Seeks Shareholder Approval for $15M Capital RaiseJanuary 16, 2025 | tipranks.comSyntara Limited to Issue 250 Million SharesDecember 11, 2024 | tipranks.comSyntara Limited Announces New Securities Issue PlanDecember 11, 2024 | tipranks.comSyntara Limited’s SNT-5505 Shows Promise in Myelofibrosis TrialDecember 9, 2024 | tipranks.comSee More Headlines Industry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryElectronic Equipment Current SymbolASX:SNT CUSIPN/A CIKN/A Webwww.syntaratx.com.au Phone61-2-9454-7200FaxN/AEmployees160Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)A($0.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-13,670,000.00 Net Margins-262.70% Pretax MarginN/A Return on Equity-191.95% Return on Assets-49.87% Debt Debt-to-Equity Ratio5.15 Current Ratio1.79 Quick RatioN/A Sales & Book Value Annual Sales$5.76 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares1,370,000,000Free FloatN/AMarket CapN/A OptionableN/A Beta0.62 (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free Report This page (ASX:SNT) was last updated on 2/23/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredElon “obliterates” Bill Gates?All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors ...Altimetry | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Syntara Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Syntara With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.